Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy:   Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

Winnie Yeo; Nicole T.Y. Ngai; CHristopher C.H. Yip; Frankie K.F. Mo; Victoria A. Yeo; Jonathan W.H. Ko; Leung V. Li; Thomas K.H. Lau; Kwai Tung Lai; Elizabeth Pang; Claudia H.W. Yip; Horatio L. Yeo; Carol Chi Hei Kwok; Stephanie W.Y. Ko; Alex Molassiotis

doi:10.2147/CMAR.S447546

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

Winnie Yeo^*
, Nicole T.Y. Ngai
, CHristopher C.H. Yip
, Frankie K.F. Mo
, Victoria A. Yeo
, Jonathan W.H. Ko
, Leung V. Li
, Thomas K.H. Lau
, Kwai Tung Lai
, Elizabeth Pang
, Claudia H.W. Yip
, Horatio L. Yeo
, Carol Chi Hei Kwok
, Stephanie W.Y. Ko
, Alex Molassiotis

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Purpose: Although risk factors related to chemotherapy-induced nausea and vomiting (CINV) have been identified in previous studies, only a few studies have evaluated the risk factors associated with contemporary antiemetic prophylaxis, including olanzapine/ aprepitant-or NEPA-containing regimens. This study aimed to identify the risk factors associated with CINV development in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy. Methods: Data from 304 patients enrolled in 3 previously reported prospective antiemetic studies were included. Multivariate logistic regression models were used to predict risk factors associated with CINV occurrence. Additionally, the likelihood of treatment failure in relation to the number of risk factors in individual patients was evaluated. Results: Multivariate analysis of the entire study group revealed that obesity status (defined as body mass index/= 25.0 kg/m2) and the use of olanzapine/aprepitant-or NEPA-containing anti-emetic regimens were associated with a high likelihood, while a history of motion sickness was associated with a lower likelihood, complete response (CR), and “no nausea” in the overall phase. A history of vomiting during pregnancy was also associated with a lower likelihood of an overall CR. Patients with an increasing number of risk factors had a higher likelihood of treatment failure and shorter time to first vomiting. Those who did not achieve CR and “no nausea” in the first cycle were less likely to achieve these parameters in the subsequent cycle of chemotherapy. Conclusion: The present study confirmed previously reported risk factors for CINV in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide. Further optimization of CINV control is required for patients with identifiable risk factors; olanzapine/aprepitant-or NEPA-containing prophylaxis are the preferred contemporary anti-emetics regimens for Chinese breast cancer patients undergoing doxorubicin and cyclophosphamide chemotherapy.

Original language	English
Pages (from-to)	283-297
Number of pages	15
Journal	Cancer Management and Research
Volume	16
DOIs	https://doi.org/10.2147/CMAR.S447546
Publication status	Published - 8 Apr 2024

Bibliographical note

(c) 2024 Yeo et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.phpand incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the workyou hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Forpermission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Data Access Statement

All data relevant to the study are included in the article or uploaded as supplementary information. The data are availablefrom the Comprehensive Cancer Trials Unit of the Department of Clinical Oncology, Chinese University of Hong Kong,but restrictions apply to the availability of these data. These data were used under permission for the current study, and soare not publicly available. Data are, however, available from the authors (W Yeo and F Mo) upon reasonable request.Data will be made available for 15 years from the start of the clinical trials.

Funding

This study was supported by an education grant from Madam Diana Hon Fun Kong Donation for Cancer Research.

Keywords

aprepitant
cytotoxic
nausea and vomiting
NEPA
olanzapine

Access to Document

10.2147/CMAR.S447546

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy
(c) 2024 Yeo et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.phpand incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the workyou hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Forpermission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Final published version, 858 KBLicence: CC BY-NC 4.0

Fingerprint

Dive into the research topics of 'Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials'. Together they form a unique fingerprint.

Cite this

Yeo, W., Ngai, N. T. Y., Yip, CH. C. H., Mo, F. K. F., Yeo, V. A., Ko, J. W. H., Li, L. V., Lau, T. K. H., Lai, K. T., Pang, E., Yip, C. H. W., Yeo, H. L., Kwok, C. C. H., Ko, S. W. Y., & Molassiotis, A. (2024). Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials. Cancer Management and Research, 16, 283-297. https://doi.org/10.2147/CMAR.S447546

@article{5cd56d12dcd647f9aacddff35325a9b6,

title = "Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials",

abstract = "Purpose: Although risk factors related to chemotherapy-induced nausea and vomiting (CINV) have been identified in previous studies, only a few studies have evaluated the risk factors associated with contemporary antiemetic prophylaxis, including olanzapine/ aprepitant-or NEPA-containing regimens. This study aimed to identify the risk factors associated with CINV development in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy. Methods: Data from 304 patients enrolled in 3 previously reported prospective antiemetic studies were included. Multivariate logistic regression models were used to predict risk factors associated with CINV occurrence. Additionally, the likelihood of treatment failure in relation to the number of risk factors in individual patients was evaluated. Results: Multivariate analysis of the entire study group revealed that obesity status (defined as body mass index/= 25.0 kg/m2) and the use of olanzapine/aprepitant-or NEPA-containing anti-emetic regimens were associated with a high likelihood, while a history of motion sickness was associated with a lower likelihood, complete response (CR), and “no nausea” in the overall phase. A history of vomiting during pregnancy was also associated with a lower likelihood of an overall CR. Patients with an increasing number of risk factors had a higher likelihood of treatment failure and shorter time to first vomiting. Those who did not achieve CR and “no nausea” in the first cycle were less likely to achieve these parameters in the subsequent cycle of chemotherapy. Conclusion: The present study confirmed previously reported risk factors for CINV in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide. Further optimization of CINV control is required for patients with identifiable risk factors; olanzapine/aprepitant-or NEPA-containing prophylaxis are the preferred contemporary anti-emetics regimens for Chinese breast cancer patients undergoing doxorubicin and cyclophosphamide chemotherapy.",

keywords = "aprepitant, cytotoxic, nausea and vomiting, NEPA, olanzapine",

author = "Winnie Yeo and Ngai, \{Nicole T.Y.\} and Yip, \{CHristopher C.H.\} and Mo, \{Frankie K.F.\} and Yeo, \{Victoria A.\} and Ko, \{Jonathan W.H.\} and Li, \{Leung V.\} and Lau, \{Thomas K.H.\} and Lai, \{Kwai Tung\} and Elizabeth Pang and Yip, \{Claudia H.W.\} and Yeo, \{Horatio L.\} and Kwok, \{Carol Chi Hei\} and Ko, \{Stephanie W.Y.\} and Alex Molassiotis",

note = "(c) 2024 Yeo et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.phpand incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the workyou hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Forpermission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).",

year = "2024",

month = apr,

day = "8",

doi = "10.2147/CMAR.S447546",

language = "English",

volume = "16",

pages = "283--297",

}

Yeo, W, Ngai, NTY, Yip, CHCH, Mo, FKF, Yeo, VA, Ko, JWH, Li, LV, Lau, TKH, Lai, KT, Pang, E, Yip, CHW, Yeo, HL, Kwok, CCH, Ko, SWY & Molassiotis, A 2024, 'Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials', Cancer Management and Research, vol. 16, pp. 283-297. https://doi.org/10.2147/CMAR.S447546

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials. / Yeo, Winnie; Ngai, Nicole T.Y.; Yip, CHristopher C.H. et al.
In: Cancer Management and Research, Vol. 16, 08.04.2024, p. 283-297.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy

T2 - Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

AU - Yeo, Winnie

AU - Ngai, Nicole T.Y.

AU - Yip, CHristopher C.H.

AU - Mo, Frankie K.F.

AU - Yeo, Victoria A.

AU - Ko, Jonathan W.H.

AU - Li, Leung V.

AU - Lau, Thomas K.H.

AU - Lai, Kwai Tung

AU - Pang, Elizabeth

AU - Yip, Claudia H.W.

AU - Yeo, Horatio L.

AU - Kwok, Carol Chi Hei

AU - Ko, Stephanie W.Y.

AU - Molassiotis, Alex

N1 - (c) 2024 Yeo et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.phpand incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the workyou hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Forpermission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PY - 2024/4/8

Y1 - 2024/4/8

N2 - Purpose: Although risk factors related to chemotherapy-induced nausea and vomiting (CINV) have been identified in previous studies, only a few studies have evaluated the risk factors associated with contemporary antiemetic prophylaxis, including olanzapine/ aprepitant-or NEPA-containing regimens. This study aimed to identify the risk factors associated with CINV development in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy. Methods: Data from 304 patients enrolled in 3 previously reported prospective antiemetic studies were included. Multivariate logistic regression models were used to predict risk factors associated with CINV occurrence. Additionally, the likelihood of treatment failure in relation to the number of risk factors in individual patients was evaluated. Results: Multivariate analysis of the entire study group revealed that obesity status (defined as body mass index/= 25.0 kg/m2) and the use of olanzapine/aprepitant-or NEPA-containing anti-emetic regimens were associated with a high likelihood, while a history of motion sickness was associated with a lower likelihood, complete response (CR), and “no nausea” in the overall phase. A history of vomiting during pregnancy was also associated with a lower likelihood of an overall CR. Patients with an increasing number of risk factors had a higher likelihood of treatment failure and shorter time to first vomiting. Those who did not achieve CR and “no nausea” in the first cycle were less likely to achieve these parameters in the subsequent cycle of chemotherapy. Conclusion: The present study confirmed previously reported risk factors for CINV in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide. Further optimization of CINV control is required for patients with identifiable risk factors; olanzapine/aprepitant-or NEPA-containing prophylaxis are the preferred contemporary anti-emetics regimens for Chinese breast cancer patients undergoing doxorubicin and cyclophosphamide chemotherapy.

AB - Purpose: Although risk factors related to chemotherapy-induced nausea and vomiting (CINV) have been identified in previous studies, only a few studies have evaluated the risk factors associated with contemporary antiemetic prophylaxis, including olanzapine/ aprepitant-or NEPA-containing regimens. This study aimed to identify the risk factors associated with CINV development in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy. Methods: Data from 304 patients enrolled in 3 previously reported prospective antiemetic studies were included. Multivariate logistic regression models were used to predict risk factors associated with CINV occurrence. Additionally, the likelihood of treatment failure in relation to the number of risk factors in individual patients was evaluated. Results: Multivariate analysis of the entire study group revealed that obesity status (defined as body mass index/= 25.0 kg/m2) and the use of olanzapine/aprepitant-or NEPA-containing anti-emetic regimens were associated with a high likelihood, while a history of motion sickness was associated with a lower likelihood, complete response (CR), and “no nausea” in the overall phase. A history of vomiting during pregnancy was also associated with a lower likelihood of an overall CR. Patients with an increasing number of risk factors had a higher likelihood of treatment failure and shorter time to first vomiting. Those who did not achieve CR and “no nausea” in the first cycle were less likely to achieve these parameters in the subsequent cycle of chemotherapy. Conclusion: The present study confirmed previously reported risk factors for CINV in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide. Further optimization of CINV control is required for patients with identifiable risk factors; olanzapine/aprepitant-or NEPA-containing prophylaxis are the preferred contemporary anti-emetics regimens for Chinese breast cancer patients undergoing doxorubicin and cyclophosphamide chemotherapy.

KW - aprepitant

KW - cytotoxic

KW - nausea and vomiting

KW - NEPA

KW - olanzapine

UR - https://www.scopus.com/pages/publications/85191174150

UR - https://www.dovepress.com/risk-factors-associated-with-chemotherapy-induced-nausea-and-vomiting--peer-reviewed-fulltext-article-CMAR

U2 - 10.2147/CMAR.S447546

DO - 10.2147/CMAR.S447546

M3 - Article

AN - SCOPUS:85191174150

VL - 16

SP - 283

EP - 297

JO - Cancer Management and Research

JF - Cancer Management and Research

ER -